Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Elixinol Wellness Limited (EXL.AX)
Sydney, NSW, AU
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +14.29% | +14.29% | -11.11% | -20.00% | -11.11% | -46.67% | -75.00% | -75.00% | -75.00% | -75.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.6% Q4'25: +63.2% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-93.7% Q4'25: -47.1% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-21.8% Q4'25: -24.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-32.1% Q4'25: -26.4% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-49.8% Q4'25: -67.9% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+65.8% Q4'25: -60.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.96× Q4'25: -0.57× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
37.13M
est: 37.20M (-0.2%)
|
30.71M
est: 31.40M (-2.2%)
|
15.01M
est: 14.90M (+0.7%)
|
9.34M
est: 9.00M (+3.8%)
|
7.06M
est: 6.56M (+7.6%)
|
8.27M
est: 8.82M (-6.2%)
|
14.96M
est: 12.50M (+19.6%)
|
15.50M
est: 21.00M (-26.2%)
|
| EBITDA |
1.08M
est: -30.44M (+103.6%)
|
-70.82M
est: -25.69M (-175.6%)
|
-95.94M
est: -42.33M (-126.7%)
|
-15.51M
est: -52.61M (+70.5%)
|
-9.28M
est: -65.84M (+85.9%)
|
-6.81M
est: -82.12M (+91.7%)
|
-4.01M
est: -55.49M (+92.8%)
|
-4.11M
est: -14.10M (+70.9%)
|
| EBIT |
-974.0K
est: -31.49M (+96.9%)
|
-73.61M
est: -26.58M (-176.9%)
|
-99.15M
est: -33.00M (-200.5%)
|
-17.00M
est: -41.02M (+58.6%)
|
-10.00M
est: -51.33M (+80.5%)
|
-7.40M
est: -64.03M (+88.4%)
|
-5.05M
est: -44.44M (+88.6%)
|
-4.98M
est: -14.93M (+66.7%)
|
| Net Income |
-860.0K
est: 10.79M (-108.0%)
|
-80.62M
est: -173.47M (+53.5%)
|
-104.51M
est: -38.03M (-174.8%)
|
-17.03M
est: -47.27M (+64.0%)
|
-10.57M
est: -59.16M (+82.1%)
|
-7.51M
est: -73.78M (+89.8%)
|
-1.72M
est: -54.06M (+96.8%)
|
-5.50M
|
| SGA |
18.18M
est: 39.26M (-53.7%)
|
25.09M
est: 33.14M (-24.3%)
|
15.74M
est: 15.73M (+0.1%)
|
16.64M
est: 9.50M (+75.1%)
|
6.74M
est: 6.92M (-2.6%)
|
7.99M
est: 9.31M (-14.2%)
|
7.87M
est: 11.46M (-31.3%)
|
5.48M
est: 19.24M (-71.5%)
|
| EPS |
-0.01
est: 0.07 (-109.3%)
|
-0.41
est: -1.12 (+63.5%)
|
-0.45
est: -0.88 (+48.7%)
|
-0.04
est: -0.29 (+85.3%)
|
-0.03
est: -0.25 (+89.6%)
|
-0.01
est: -0.06 (+80.2%)
|
-0.01
est: -0.06 (+82.2%)
|
-0.02
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Natalie Butler | Chief Executive Officer & Executive Director | 310.5K | female |
| Adam Dimitropoulos | Chief Financial Officer | 153.2K | male |
| Glen Zurcher | Account Director of Investor Relations Department | — | — |
| Mariia Skorikova | Joint Company Secretary | — | female |
| Melanie Leydin | Company Secretary | — | female |
| Tony Di Pietro | Joint Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EXL.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
